WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL

A PRoliferation-Inducing Ligand (APRIL) is a key driver in the immune-related pathogenesis of immunoglobulin A nephropathy (IgAN). Sibeprenlimab, a humanized IgG2 monoclonal antibody that blocks APRIL, demonstrated acceptable safety with robust urine protein creatinine ratio (uPCR) reduction and eGFR stability at 12 months in a Phase 2 study of patients with IgAN.1 Defined criteria for remission in IgAN are varied and include reduction of proteinuria below certain thresholds (<1.0 g/d, <500 mg/d and <300 mg/day) as well as remission in hematuria (reduction in red blood cell [RBC] count to <5 RBC/high power field [HPF]).2–4 We report the effect of sibeprenlimab on hematuria resolution and remission of proteinuria.